TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate

MLA

Kabagambe Edmond K, et al. “TCF7L2 Polymorphisms and Inflammatory Markers before and after Treatment with Fenofibrate.” Diabetology & Metabolic Syndrome, vol. 1, no. 1, Oct. 2009, p. 16. EBSCOhost, https://doi.org/10.1186/1758-5996-1-16.

APA

Kabagambe Edmond K, Glasser Stephen P, Ordovas Jose M, Warodomwichit Daruneewan, Tsai Michael Y, Hopkins Paul N, Borecki Ingrid B, Wojczynski Mary, & Arnett Donna K. (2009). TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate. Diabetology & Metabolic Syndrome, 1(1), 16. https://doi.org/10.1186/1758-5996-1-16

Chicago

Kabagambe Edmond K, Glasser Stephen P, Ordovas Jose M, Warodomwichit Daruneewan, Tsai Michael Y, Hopkins Paul N, Borecki Ingrid B, Wojczynski Mary, and Arnett Donna K. 2009. “TCF7L2 Polymorphisms and Inflammatory Markers before and after Treatment with Fenofibrate.” Diabetology & Metabolic Syndrome 1 (1): 16. doi:10.1186/1758-5996-1-16.